Citadel Advisors’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Citadel Advisors’s Portfolio CANF Stock Details CANF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$106K	Buy	+34,150	New	+$141K	﹤0.01%	11970
2024 Q2	–	Sell	-709	Closed	-$31.5K	–	14317
2024 Q1	$31.5K	Buy	+709	New	+$29.6K	﹤0.01%	12656
2022 Q2	–	Sell	-57	Closed	-$14K	–	12947
2022 Q1	$14K	Buy	+57	New	+$13.2K	﹤0.01%	13325
2021 Q3	–	Sell	-193	Closed	-$88K	–	13839
2021 Q2	$88K	Sell	193 -107	-36%	-$46.9K	﹤0.01%	13017
2021 Q1	$148K	Buy	+300	New	+$130K	﹤0.01%	12051
2020 Q4	–	Sell	-59	Closed	-$21K	–	10936
2020 Q3	$21K	Buy	+59	New	+$24.6K	﹤0.01%	9841
2020 Q2	–	Sell	-101	Closed	-$26K	–	9808
2020 Q1	$26K	Buy	+101	New	+$38.7K	﹤0.01%	9229
2019 Q4	–	Sell	-116	Closed	-$48K	–	9144
2019 Q3	$48K	Buy	+116	New	+$61.5K	﹤0.01%	8716
2017 Q4	–	Sell	-4	Closed	-$20K	–	7984
2017 Q3	$20K	Sell	4 -2	-33%	-$10.3K	﹤0.01%	7356
2017 Q2	$30K	Buy	+6	New	+$32.9K	﹤0.01%	7201
2017 Q1	–	Sell	-5	Closed	-$34K	–	7458
2016 Q4	$34K	Buy	+5	New	+$35K	﹤0.01%	6958
2015 Q2	–	Sell	-3	Closed	-$23K	–	8746
2015 Q1	$23K	Buy	+3	New	+$36.1K	﹤0.01%	7819

Other funds holding CANF

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Citadel Advisors's CANF Position: Q1 2026 in Review

Citadel Advisors opened a new position in Can-Fite BioPharma American Depositary Shares (CANF) in Q1 2026: 34,150 shares worth $106K. The stake represents ﹤0.01% of the portfolio and ranks #11970 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CANF as recently as Q1 2024.

Citadel Advisors first reported a position in CANF in Q1 2015 and has held it in 12 quarters since. The position peaked at $148K in Q1 2021. 14 funds tracked by Wall St. Rank hold CANF as of Q1 2026.

Citadel Advisors held 34,150 shares of Can-Fite BioPharma American Depositary Shares worth $106K as of Q1 2026.
Can-Fite BioPharma American Depositary Shares was a new Citadel Advisors position in Q1 2026.
Can-Fite BioPharma American Depositary Shares made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11970 holding.
Citadel Advisors first reported a position in Can-Fite BioPharma American Depositary Shares in Q1 2015 and has held it in 12 quarters since.
Citadel Advisors's Can-Fite BioPharma American Depositary Shares position peaked at $148K in Q1 2021.
14 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.